News BioNTech flips its cancer bispecific to BMS for a big profit Bristol Myers Squibb is spending big to avoid being left behind in the race to develop a much-touted class of bispecific antibodies for cancer.
Market Access A year of major M&A ahead? The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.
Sales & Marketing BMS’ Catherine Owen on pharma commercialisation: the pharmap... Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of pharma commercialisation and comm
Sales & Marketing Deep Dive: Communications and Commercialisation The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation.
Views & Analysis Have a chat to help others through loneliness Looking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s gone’ comes to mind.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.